Dana DiBenedetti, PhD

Exploring Patient Experiences Taking Adjunctive Brexpiprazole for Major Depressive Disorder (MDD): Post-hoc Analysis of Exit Interview Data

Background: The efficacy and safety of adjunctive brexpiprazole, a serotonin–dopamine activity modulator, has been demonstrated in clinical studies in adults with MDD and inadequate respo...

Michelle Brown , PhD;

Catherine Gupta , PhD;

Dana DiBenedetti , PhD;

Michael Thase , MD;

Zahinoor Ismail , MD;

Roger McIntyre , MD, FRCPC;

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

H. Lundbeck ;

11/22/2019

Assessing Experiences, Attitudes, and Perceptions Associated With Treatment-Resistant Schizophrenia: Caregiver Focus Groups

Background: Treatment-resistant schizophrenia (TRS), defined as schizophrenia not responding to two trials of antipsychotics (APs) of adequate dose and duration, affects about one-third o...

Dana DiBenedetti , PhD;

Dawn Velligan , PhD;

Steven Kymes , PhD;

Anne-Marie Kelnaes , MA;

Thomas Brevig , MD, PharmD;

03/01/2019